Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 12.45

From 52W high−43.38%

Volume28.98M

Market capCNY 30.71B

P/E (TTM)−2.1x

P/S (TTM)3.5x

Div yield—

Key dataSep 18, 2026

Open

CNY 12.45

From 52W high

−43.38%

Volume

28.98M

Market cap

CNY 30.71B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.2x

P/E (TTM)

−2.1x

RSI (14)

47.0

MomentumView details →

1D Return

−7.70%

YTD Return

−32.43%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−2.1x

EV/EBITDA

−2.2x

EV/Sales

4.2x

P/S (TTM)

3.5x

P/B (TTM)

2.0x

ProfitabilityView details →

Gross Margin

6.58%

Net Margin

−168.87%

EBITDA Margin

−193.47%

ROE (TTM)

−95.68%

ROA (TTM)

−50.82%

Asset Turnover

0.29x

GrowthView details →

Revenue YoY

−48.46%

EPS YoY

—

FCF YoY

+680.14%

Revenue CAGR 3Y

−38.37%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−7.70%

YTD Return

−32.43%

1Y Return

−41.89%

RSI (14)

47.0

vs 50D SMA

−2.17%

vs 200D SMA

−16.89%

Capital & dividendView details →

Debt/Equity

0.51x

Current Ratio

3.14x

Quick Ratio

2.46x

Div Yield

—

Div Rate

—

Div Growth 1Y

+100.00%

EarningsView details →

EPS (Actual)

−CNY 0.18

EPS Surprise

−999.90%

Beats (12Q)

0/12

Next Q EPS Est

−CNY 0.10

Avg Surprise (4Q)

−999.90%

Rev Surprise

−24.77%

Financials snapshotView financials →

Revenue (TTM)

8.75B

Net Income (TTM)

−14.78B

Op. CF (TTM)

5.11B

Next earningsOct 23, 2026 →

Latest newsMore news →

Chongqing Chenan Biopharmaceutical, a controlled subsidiary of Zhifei Biological, launched its self-developed liraglutide injection (brand name Dashuchen) into clinical use, with the first nationwide injection administered at Banan Hospital Affiliated to Chongqing Medical University.9d ago

Zhifei Biological's controlled subsidiary Chongqing Chen'an Biopharmaceutical received acceptance notices from China's National Medical Products Administration for its production registration applications for semaglutide injection, a self-developed biosimilar for type 2 diabetes.12d ago

Similar companies

东阿阿胶000423.SZ 汇绿生态001267.SZ 蔚蓝锂芯002245.SZ 章源钨业002378.SZ 新希望000876.SZ 欧陆通300870.SZ Find similar companies →

Latest newsMore news →

Chongqing Chenan Biopharmaceutical, a controlled subsidiary of Zhifei Biological, launched its self-developed liraglutide injection (brand name Dashuchen) into clinical use, with the first nationwide injection administered at Banan Hospital Affiliated to Chongqing Medical University.9d ago Zhifei Biological's controlled subsidiary Chongqing Chen'an Biopharmaceutical received acceptance notices from China's National Medical Products Administration for its production registration applications for semaglutide injection, a self-developed biosimilar for type 2 diabetes.12d ago Zhifei Biological's subsidiary Chongqing Chen'an Biotech officially launched its liraglutide injection (Dashuchen) into the market with a shipment ceremony on September 4, 2026.16d ago